
Accelerating the Business of Life Science



"We have a tremendous opportunity to galvanize economic growth in Southeastern Pennsylvania by building on our depth and breadth in the life sciences, particularly in biopharmaceuticals and medical devices. With the funding from the Commonwealth, BioAdvance will provide critical capital and other support to help entrepreneurs move science from the laboratory into successful businesses."

3701 Market Street
Philadelphia, PA 19104
p: 215-966-6214
f: 215-966-6215
www.bioadvance.com

Barbara S. Schilberg, Managing Director and CEO

Barbara has 20 years of experience in the biopharmaceutical industry. As a senior executive of four emerging life sciences companies, she brings broad experience in the key elements needed to build successful companies, including public and private financings, intellectual property protection, corporate partnering arrangements and the management of research programs. Before joining the industry, she specialized in representing biopharmaceutical companies and research institutions in the commercialization of technology.

While a partner in the Philadelphia office of Morgan, Lewis & Bockius, she developed novel strategies for the licensing and commercialization of life sciences technology on behalf of biopharmaceutical companies such as Cephalon, Inc. and non-profit research institutions such as the University of Pennsylvania, The Wistar Institute and Thomas Jefferson University. Her practice supported a wide range of industry activities, including venture capital financings, IPOs and other public offerings, marketing, co-development and joint-venture arrangements, sponsored research, and technology transfers.

She was recruited in 1994 to Cephalon, Inc. in West Chester, PA where she served as Senior Vice President and General Counsel and as a member of the executive committee. In addition to those responsibilities, she led a multi-disciplinary team charged with completing Phase III clinical trials and preparing a new drug application for PROVIGIL[®] (modafinil), which was approved by the FDA in December 1998. She joined Incara Pharmaceuticals in 1998 as Executive Vice President and General Counsel. As part of her responsibilities she managed a research operation in Princeton, NJ engaged in discovering new antibacterial therapeutics, and continued in that capacity after the operation's acquisition by Advanced Medicine (now Theravance) in 2000. Barbara was most recently employed in senior management at Locus Discovery, Inc., an emerging pharmaceutical company in Blue Bell, PA engaged in computational drug design.

Ms. Schilberg received her J.D. from the University of Virginia and clerked with the Honorable Edward R. Becker, now Senior Judge of the U.S. Court of Appeals for the Third Circuit.

Contact: bschilberg@bioadvance.com